Neovascularization in human atherosclerosis

Circulation

Volumn 113, Issue 18, 2006, Pages 2245-2252

  Moreno, Pedro R ^a   Purushothaman, K Raman ^a   Sirol, Marc ^a   Levy, Andrew P ^b   Fuster, Valentin ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Angiogenesis; Aorta; Atherosclerosis; Hypoxia; Neovascularization

Indexed keywords

ANGIOTENSIN II; HAPTOGLOBIN; HEMOGLOBIN; VASCULOTROPIN;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL PERMEABILITY; HUMAN; LEUKOCYTE; LIPID STORAGE; MACROPHAGE ACTIVATION; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; REVIEW; VASA VASORUM;

ANGIOTENSIN II; ANIMALS; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; ATHEROSCLEROSIS; BLOOD PROTEINS; CAPILLARY PERMEABILITY; CELL HYPOXIA; CHEMOTAXIS, LEUKOCYTE; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; HEMORRHAGE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MACROPHAGE ACTIVATION; MEMBRANE LIPIDS; MODELS, ANIMAL; NEOVASCULARIZATION, PHYSIOLOGIC; OXIDATIVE STRESS; SUS SCROFA; SYMPATHETIC NERVOUS SYSTEM; TUNICA INTIMA; VASA VASORUM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33646816714     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.578955     Document Type: Review

References (76)

1. Williams JK, Heistad DD. Structure and function of vasa vasorum. Trends Cardiovasc Med. 1996;6:53-57.
2. Heistad DD, Marcus ML, Law EG, Armstrong ML, Ehrhardt JC, Abboud FM. Regulation of blood flow to the aortic media in dogs. J Clin Invest. 1978;62:133-140.
3. Scotland RS, Vallance P, Ahluwalia A. Endothelin alters the reactivity of vasa vasorum: mechanisms and implications for conduit vessel physiology and pathophysiology. Br J Pharmacol. 1999;128:1229-1234.
4. Ohhira O, Ohhashi T. Effects of aortic pressure and vasoactive agents on the vascular resistance of the vasa vasorum in canine isolated thoracic aorta. J Physiol 1992;453:233-245.
5. Semenza GL. Expression of hypoxia-inducible factor 1: mechanisms and consequences. Biochem Pharmacol. 2000;59:47-53.
6. North S, Moenner M, Bikfalvi A. Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. Cancer Lett. 2005;218:1-14.
7. Gorlach A, Diebold I, Schini-Kerth VB, Berchner-Pfannschmidt U, Roth U, Brandes RP, Kietzmann T, Busse R. Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: role of the p22 (phox)-containing NADPH oxidase. Circ Res. 2001;89:47-54.
8. Stefanadis CI, Karayannacos PE, Boudoulas HK, Stratos CG, Vlachopoulos CV, Dontas IA, Toutouzas PK. Medial necrosis and acute alterations in aortic distensibility following removal of the vasa vasorum of canine ascending aorta. Cardiovasc Res. 1993;27:951-956.
9. Stefanadis C, Karayannacos P, Boudoulas H, Stratos C, Filippides T, Agapitos M, Toutouzas P. Effect of vasa vasorum flow on structure and function of the aorta in experimental animals. Circulation. 1995;91:2669-2678.
10. Booth RF, Martin JF, Honey AC, Hassall DG, Beesley JE, Moncada S. Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation. Atherosclerosis. 1989;76:257-268.
11. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671-674.
12. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9: 653-660.
13. Frantz S, Vincent KA, Feron O, Kelly RA. Innate immunity and angiogenesis. Circ Res. 2005;96:15-26.
14. Isner JM. Cancer and atherosclerosis: the broad mandate of angiogenesis. Circulation. 1999;99:1653-1655.
15. Groszek E, Grundy SM. The possible role of the arterial microcirculation in the pathogenesis of atherosclerosis. J Chronic Dis. 1980;33:679-684.
16. Kwon HM, Sangiorgi G, Ritman EL, McKenna C, Holmes DR Jr, Schwartz RS, Lerman A. Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J Clin Invest. 1998;101: 1551-1556.
17. Herrmann J, Lerman LO, Rodriguez-Porcel M, Holmes DR Jr, Richardson DM, Ritman EL, Lerman A. Coronary vasa vasorum neovascularization precedes epicardial endothelial dysfunction in experimental hypercholesterolemia. Cardiovasc Res. 2001;51:762-766.
18. Jeziorska M, Woolley DE. Neovascularization in early atherosclerotic lesions of human carotid arteries: its potential contribution to plaque development. Hum Pathol. 1999;30:919-925.
19. Barger AC, Beeuwkes R III, Lainey LL, Silverman KJ. Hypothesis: vasa vasorum and neovascularization of human coronary arteries: a possible role in the pathophysiology of atherosclerosis. N Engl J Med. 1984;310: 175-177.
20. Zhang Y, Cliff WJ, Schoefl GI, Higgins G. Immunohistochemical study of intimal microvessels in coronary atherosclerosis. Am J Pathol. 1993;143:164-172.
21. Kumamoto M, Nakashima Y, Sueishi K. Intimal neovascularization in human coronary atherosclerosis: its origin and pathophysiological significance. Hum Pathol. 1995;26:450-456.
22. de Boer OJ, van der Wal AC, Teeling P, Becker AE. Leucocyte recruitment in rapture prone regions of lipid-rich plaques: a prominent role for neovascularization? Cardiovasc Res. 1999;41:443-449.
23. O'Brien KD, Allen MD, McDonald TM, Chait A, Harlen JM, Fishbein D, McCarty J, Ferguson M, Hudkins K, Benjamin CD. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. J Clin Invest. 1993;92:945-951.
24. O'Brien KD, McDonald TM, Chait A, Allen MD, Alpers CE. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation. 1996;93:672-682.
25. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol. 2004;44:2293-2300.
26. Moreno PR, Purushothaman KR, Fuster V, Echeverri D, Truszczynska H, Sharma SK, Badimon JJ, O'Connor WN. Plaque neovascularization is increased in raptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation. 2004;110:2032-2038.
27. Moreno PR Purashothaman KR, O'Connor WN, Kini A, Sirol M, Sharma SK, Fuster V. Microvessel sprouting, red blood cell extravasation, and peri-vascular inflammation is increased in plaques from patients with diabetes mellitus. J Am Coll Cardiol. 2005;45:430A.
28. Moreno PR Purushothaman KR, O'Connor WN, Sirol M, Sharma SK, Fuster V. Intraplaque hemorrhage increases peri-hemorrhage inflammation and macrophage erythrophagocytosis in high-risk atherosclerotic plaques from patients with diabetes mellitus. Circulation. 2005;112:II-210.
29. Moreno PR, Purashothaman KR, Fuster V, O'Connor WN. Intimomedial interface damage and adventitial inflammation is increased beneath disrupted atherosclerosis in the aorta: implications for plaque vulnerability. Circulation. 2002;105:2504-2511.
30. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque part I: evolving concepts. J Am Coll Cardiol. 2005;46:937-954.
31. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306-1309.
32. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983-985.
33. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond). 2005;109:227-241.
34. Bates DO, Curry FE. Vascular endothelial growth factor increases microvascular permeability via a Ca(2+)-dependent pathway. Am J Physiol. 1997;273:H687-H694.
35. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med. 1994;330:1431-1438.
36. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820.
37. De Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA. The transcription factor NF-κB and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol. 2000;20:e83-e88.
38. Paterson JC, Moffatt T, Mills J. Hemosiderin deposition in early atherosclerotic plaques. Arch Pathol. 1956;61:1134-1140.
39. Kockx MM, Cromheeke KM, Knaapen MW, Bosmans JM, De Meyer GR, Herman AG, Bult H. Phagocytosis and macrophage activation associated with hemorrhagic microvessels in human atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:440-446.
40. Arbustini E, Morbini P, D'Armini AM, Repetto A, Minzioni G, Piovella F, Vigano M, Tavazzi L. Plaque composition in plexogenic and thromboembolic pulmonary hypertension: the critical role of thrombotic material in pultaceous core formation. Heart. 2002;88:177-182.
41. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, Guerrero LJ, Hayase M, Kutys R, Narula J, Finn AV, Virmani R. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med. 2003;349:2316-2325.
42. Vlodavsky I, Freidmann Y. Molecular properties and involvement of heparinase in cancer metastasis and angiogenesis. J Clin Invest. 2001; 108:341-347.
43. Melamed-Frank M, Lache O, Enav BI, Szafranek T, Levy NS, Ricklis RM, Levy AP. Structure/function analysis of the anti-oxidant properties of haptoglobin. Blood. 2001;98:3693-3698.
44. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem. 1996;42:1589-1600.
45. Graversen JH, Madsen M, Moestrup SK. CD163: a signal receptor scavenging haptoglobin-hemoglobin complexes from plasma. Int J Biochem Cell Biol. 2002;34:309-314.
46. Vanden Heuvel MM, Tensen CP, Van As JH, Van den Berg TK, Fluitsma DM, Dijikstra CD, Dopp EA, Droste A, Vangaalen FA, Sorg C, Hogger P, Beelen RH. Regulation of CD163 on macrophages: cross linking of CD163 induces signaling and activation. J Leuk Biol. 1999;66:858-866.
47. Philippidis P, Mason JC, Evans BJ, Nadra I, Taylor KM, Haskard DO, Landis RC. Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: antiinflammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res. 2004;94:119-126.
48. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
49. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, Soubrier F, Esposito B, Duez H, Fievet C, staels B, Duverger N. Scherman D, Tedgui A. Protective role of interleukin-10 in atherosclerosis. Circ Res. 1999;85:e17-224.
50. Schaer DJ. The macrophage hemoglobin scavenger receptor CD163 as a genetically determined disease modifying pathway in atherosclerosis. Atherosclerosis. 2002;163:199-201.
51. Bowman BH, Kurosky A. Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Adv Hum Genet. 1982;12:189-261.
52. Bamm VV, Tsemakhovich VA, Shaklai M, Shklai N. Haptoglobin phenotypes differ in their ability to inhibit heme transfer from hemoglobin to LDL. Biochemistry. 2004;43:3899-3906.
53. Asleh R, Marsh S, Shilkrut M, Binah O, Guetta J, Lejbkowicz F, Enav B, Shehadeh N, Kanter Y, Lache O, Cohen O, Levy NS, Levy AP. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res. 2003;92:1193-1200.
54. Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res. 2005;96:435-441.
55. Levy AP. Haptoglobin: a major susceptibility gene for diabetic cardiovascular disease. Isr Med Assoc J. 2004;6:308-310.
56. Levy AP, Roguin A, Hochberg I, Herer P, Marsh S, Nakhoul FM, Skorecki K. Haptoglobin phenotype and vascular complications in patients with diabetes. N Engl J Med. 2000;343:969-970.
57. Levy AP, Hochberg I, Jablonski K, Resnick HE, Lee ET, Best L, Howard BV. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the Strong Heart Study. J Am Coll Cardiol. 2002;40:1984-1990.
58. Roguin A, Koch W, Kastrati A, Aronson D, Schomig A, Levy AP. Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care. 2003;26:2628-2631.
59. Suleiman M, Aronson D, Asleh R, Kapeliovich MR, Roguin A, Meisel SR, Shochat M, Sulieman A, Reisner SA, Markiewicz W, Hammerman H, Lotan R, Levy NS, Levy A. Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes. 2005;54:2802-2806.
60. Moreno PR, Purushothaman KR, O'Connor WN, Kini A, Sirol M, Sharma SK, Fuster V. Increased inflammation and neovascularization in diabetes atherosclerosis is no longer present in fibrocalcific plaques: a marker of stabilization? J Am Coll Cardiol. 2005;45:A402.
61. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D, Weinberger J, Wentzel J, Mizsei G, Mercuri M, Badimon JJ. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation. 2002;106:2884-2887.
62. Williams JK, Armstrong ML, Heistad DD. Vasa vasorum in atherosclerotic coronary arteries: responses to vasoactive stimuli and regression of atherosclerosis. Circ Res. 1988;62:515-523.
63. Badimon JJ, Badimon L, Galvez A, Dische R, Fuster V. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab Invest. 1989;60:455-461.
64. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 1990;85:1234-1241.
65. Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E, Lo KM, Gillies S, Javaherian K, Folkman J. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A. 2003;100:4736-4741.
66. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation. 1999;99:1726-1732.
67. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M, Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl Med. 2005;353:999-1007.
68. Kerwin W, Hooker A, Spilker M, Vicini P, Ferguson M, Hatsukami T, Yuan C. Quantitative magnetic resonance imaging analysis of neovasculature volume in carotid atherosclerotic plaque. Circulation. 2003;107:851-856.
69. Turetschek K, Huber S, Floyd E, Helbich T, Roberts TP, Shames DM, Tarlo KS, Wendland MF, Brasch RC. MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation. Radiology. 2001;218:562-569.
70. Feinstein SB. The powerful microbubble: from bench to bedside, from intravascular indicator to therapeutic delivery system, and beyond. Am J Physiol. 2004;287:H450-H457.
71. Carlier S, Kakadiaris IA, Dib N, Vavuranakis M, Stefanadis C, O'Malley SM, Hartley CJ, Metcalfe R, Mehran R, Falk E, Stone G, Leon M, Naghavi M. Vasa vasorum imaging: a new window to the clinical detection of vulnerable atherosclerotic plaques. Curr Atheroscler Rep. 2005;7:164-169.
72. Jaffer FA, Weissleder R. Seeing within: molecular imaging of the cardiovascular system. Circ Res. 2004;94:433-445.
73. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen JS, Lacy EK, Robertson JD, Lanza GM, Wickline SA. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation. 2003;108:2270-2274.
74. Matter CM, Schuler PK, Alessi P, Meier P, Ricci R, Zhang D, Halin C, Castellani P, Zardi L, Hofer CK, Montani M, Neri D, Luscher TF. Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin. Circ Res. 2004;95:1225-1233.
75. Castellani P, Borsi L, Carnemolla B, Biro A, Dorcaratto A, Viale GL, Neri D, Zardi L. Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol. 2002;161:1695-1700.
76. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res. 2005;96:327-336.